NICE and Flatiron Health partner to develop RWE research methodologies

14th July 2020 (Last Updated July 14th, 2020 17:28)

The National Institute for Health and Care Excellence (NICE) has partnered with oncology research and technology firm Flatiron Health.

NICE and Flatiron Health partner to develop RWE research methodologies
The three-year collaboration with NICE marks Flatiron’s first partnership beyond the US. Credit: Florey Institute.

The National Institute for Health and Care Excellence (NICE) has partnered with oncology research and technology firm Flatiron Health.

The partnership is aimed at exploring ways of how real-world evidence (RWE) can inform the clinical and cost effectiveness of health technologies.

It will enable NICE to expand the use of real-world data (RWD) in service of better outcomes for cancer patients in the UK.

Under the strategic collaboration, experts from Flatiron Health and NICE will conduct research that strengthens Flatiron expertise generated from its electronic health record (EHR)-derived database.

According to the companies, no individual patient data will be shared.

An initial research project, which is currently underway, will compare survival estimates from clinical trials to survival data observed in actual patient records.

By comparing this data, opportunities to reduce uncertainty in the estimation of long-term outcomes will be assessed.

The three-year collaboration with NICE marks Flatiron’s first partnership beyond the US and with an Health Technology Appraisal (HTA) body.

Flatiron Health co-founder, president and COO Zach Weinberg said: “We are very proud to partner with NICE to learn together, to continue to contribute to standards development and ensure that patient experiences inform research and drive better outcomes.

“The current pandemic increasingly highlights the important role of real-world data in healthcare decision-making, for Covid-19, for cancer, and for many other urgent health priorities.”

In February 2018, NICE gave its support for EUSA Pharma’s drug Fotivda (tivozanib) as a first-line treatment for advanced renal cell carcinoma (RCC). RCC is the most common form of kidney cancer, making up 80% of cases.